应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01672 歌礼制药-B
交易中 12-23 09:56:09
2.850
+0.070
+2.52%
最高
2.890
最低
2.790
成交量
73.50万
今开
2.860
昨收
2.780
日振幅
3.60%
总市值
27.70亿
流通市值
27.70亿
总股本
9.72亿
成交额
208.96万
换手率
0.08%
流通股本
9.72亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
歌礼制药-B(01672)12月20日斥资7.3万港元回购2.9万股
智通财经 · 12-20 18:53
歌礼制药-B(01672)12月20日斥资7.3万港元回购2.9万股
【券商聚焦】方正证券维持歌礼制药(01672)推荐评级 ASC47联合司美格鲁肽在减重保肌效果上优于单药治疗
金吾财讯 · 12-20 14:12
【券商聚焦】方正证券维持歌礼制药(01672)推荐评级 ASC47联合司美格鲁肽在减重保肌效果上优于单药治疗
歌礼制药-B现涨超14% 治疗肥胖症候选药ASC47研究显示出鼓舞疗效
新浪港股 · 12-20 10:01
歌礼制药-B现涨超14% 治疗肥胖症候选药ASC47研究显示出鼓舞疗效
异动解读 | 歌礼制药-B(01672)盘中大涨14.63% 减肥药ASC47令人鼓舞疗效
异动解读 · 12-20
异动解读 | 歌礼制药-B(01672)盘中大涨14.63% 减肥药ASC47令人鼓舞疗效
港股异动 | 歌礼制药-B(01672)涨超13% 治疗肥胖症候选药ASC47研究显示出鼓舞疗效
智通财经 · 12-20
港股异动 | 歌礼制药-B(01672)涨超13% 治疗肥胖症候选药ASC47研究显示出鼓舞疗效
歌礼制药－Ｂ(01672)股价显著上升12.195%，现价港币$2.76
阿斯达克财经 · 12-20
歌礼制药－Ｂ(01672)股价显著上升12.195%，现价港币$2.76
歌礼制药(01672)盘初升逾5% ASC47与司美格鲁肽联合用药减重表现积极
金吾财讯 · 12-20
歌礼制药(01672)盘初升逾5% ASC47与司美格鲁肽联合用药减重表现积极
【特约大V】邓声兴：美联储暂缓减息拖累 中港股市偏弱
金吾财讯 · 12-20
【特约大V】邓声兴：美联储暂缓减息拖累 中港股市偏弱
金十数据全球财经早餐 | 2024年12月20日
金十数据 · 12-20
金十数据全球财经早餐 | 2024年12月20日
歌礼制药-B(01672)12月19日斥资63.44万港元回购26万股
智通财经 · 12-19
歌礼制药-B(01672)12月19日斥资63.44万港元回购26万股
歌礼制药-B(01672)下跌11.27%，报2.52元/股
金融界 · 12-19
歌礼制药-B(01672)下跌11.27%，报2.52元/股
港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.
美港电讯 · 12-19
港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.
歌礼制药减重药物ASC47联合用药显著优于单药疗法
财中社 · 12-19
歌礼制药减重药物ASC47联合用药显著优于单药疗法
异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关
异动解读 · 12-19
异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关
歌礼制药-B盘中异动 股价大跌5.28%
市场透视 · 12-19
歌礼制药-B盘中异动 股价大跌5.28%
金十数据全球财经早餐 | 2024年12月19日
金十数据 · 12-19
金十数据全球财经早餐 | 2024年12月19日
歌礼制药(01672.HK)首创治疗肥胖症候选药ASC47研究显示出鼓舞疗效
阿斯达克财经 · 12-19
歌礼制药(01672.HK)首创治疗肥胖症候选药ASC47研究显示出鼓舞疗效
港股公告掘金 | 首程控股拟约14.566亿港元向首钢控股出售约6.07亿股首钢资源股份
智通财经 · 12-18
港股公告掘金 | 首程控股拟约14.566亿港元向首钢控股出售约6.07亿股首钢资源股份
歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果
智通财经 · 12-18
歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果
歌礼制药：恒指收涨 0.83% 生物医药走强
和讯网 · 12-18
歌礼制药：恒指收涨 0.83% 生物医药走强
加载更多
公司概况
公司名称：
歌礼制药-B
所属市场：
SEHK
上市日期：
--
主营业务：
歌礼制药有限公司是一家主要从事医药产品的研发、生产、营销及销售的中国投资控股公司。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。病毒性疾病产品管线包括利托那韦、盐酸拉维达韦、达诺瑞韦钠等。非酒精性脂肪性肝炎产品管线包括ASC40、ASC41、ASC42等。肿瘤产品管线包括ASC60、ASC61等。
发行价格：
--
{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":2.85,"timestamp":1734918937934,"preClose":2.78,"halted":0,"volume":735000,"delay":0,"floatShares":972000000,"shares":972000000,"eps":-0.14343949,"marketStatus":"交易中","marketStatusCode":2,"change":0.07,"latestTime":"12-23 09:56:09","open":2.86,"high":2.89,"low":2.79,"amount":2089600,"amplitude":0.035971,"askPrice":2.85,"askSize":9000,"bidPrice":2.83,"bidSize":12000,"shortable":0,"etf":0,"ttmEps":-0.2648919403764552,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1734926400000},"adr":0,"listingDate":1533052800000,"adjPreClose":2.78,"openAndCloseTimeList":[[1734917400000,1734926400000],[1734930000000,1734940800000]],"volumeRatio":1.411955,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"2492413265","title":"歌礼制药-B(01672)12月20日斥资7.3万港元回购2.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492413265","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492413265?lang=zh_cn&edition=full","pubTime":"2024-12-20 18:53","pubTimestamp":1734692035,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2024年12月20日斥资7.3万港元回购股份2.9万股，每股回购价格为2.5-2.52港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01477","BK1191","01672","BK1161","BK1574"],"gpt_icon":0},{"id":"2492614254","title":"【券商聚焦】方正证券维持歌礼制药(01672)推荐评级 ASC47联合司美格鲁肽在减重保肌效果上优于单药治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2492614254","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492614254?lang=zh_cn&edition=full","pubTime":"2024-12-20 14:12","pubTimestamp":1734675137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 方正证券发研指，歌礼制药 近日宣布治疗肥胖症的减重不减肌候选药物ASC47联合司美格鲁肽的临床前减重数据。司美格鲁肽单药治疗无法恢复肥胖小鼠的体成分至健康水平。该行续指，ASC47在澳大利亚进行的低密度脂蛋白胆固醇偏高受试者I期单剂量递增研究当前递增至90mg，期中数据显示ASC47皮下注射具有良好的耐受性。IIa期研究：ASC47正在澳大利亚进行肥胖症患者的IIa期研究，顶线数据预计将于2025年第二季度公布。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1950055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","01672","601901"],"gpt_icon":0},{"id":"2492455897","title":"歌礼制药-B现涨超14% 治疗肥胖症候选药ASC47研究显示出鼓舞疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2492455897","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492455897?lang=zh_cn&edition=full","pubTime":"2024-12-20 10:01","pubTimestamp":1734660060,"startTime":"0","endTime":"0","summary":" 歌礼制药-B早盘上涨14.23%，现报2.81港元，成交额568.30万港元。 歌礼制药日前公告称，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖小鼠模型研究中显示令人鼓舞的疗效。ASC47是歌礼自主研发的脂肪靶向，具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。据悉，ASC47当前正在澳洲进行肥胖症患者临床试验，IIa期研究顶线数据预计将于2025年第二季度公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-20/doc-ineaamez6092701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01672","01477","BK1515","BK1161","BK1191"],"gpt_icon":0},{"id":"1122896149","title":"异动解读 | 歌礼制药-B(01672)盘中大涨14.63% 减肥药ASC47令人鼓舞疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1122896149","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122896149?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:52","pubTimestamp":1734659557,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672)今日盘中大涨超14%,引发市场广泛关注。\n\n导致该股大涨的主要原因是,歌礼制药旗下减肥药物ASC47在研究中显示出令人鼓舞的疗效。公司公告称,同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖小鼠模型研究中疗效突出。ASC47是歌礼自主研发的脂肪靶向药物,具有独特差异化特性,能在脂肪组织中产生较高浓度。\n\n目前ASC47正在澳洲进行临床试验,其II期研究顶线数据预计2025年第二季度公布。市场对该新药前景抱有较高期待,因此推动公司股价今日大涨。但后续仍需等待临床数据的进一步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01672"],"gpt_icon":0},{"id":"2492375458","title":"港股异动 | 歌礼制药-B(01672)涨超13% 治疗肥胖症候选药ASC47研究显示出鼓舞疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2492375458","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492375458?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:46","pubTimestamp":1734659177,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B涨超13%，截至发稿，涨13.01%，报2.78港元，成交额318.06万港元。消息面上，歌礼制药日前公告称，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖小鼠模型研究中显示令人鼓舞的疗效。据悉，ASC47当前正在澳洲进行肥胖症患者临床试验，IIa期研究顶线数据预计将于2025年第二季度公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","BK1161","BK1515","01477","BK1191"],"gpt_icon":0},{"id":"2492453927","title":"歌礼制药－Ｂ(01672)股价显著上升12.195%，现价港币$2.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2492453927","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492453927?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:45","pubTimestamp":1734659100,"startTime":"0","endTime":"0","summary":"[上升股]歌礼制药－Ｂ(01672) 股价在上午09:45比前收市价显著上升12.195%，现股价为港币$2.76。至目前为止，今日最高价为$2.76，而最低价为$2.45。总成交量为102.5万股，总成交金额为港币$270.986万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241220418/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01672","BK1574","01477","BK1191","BK1515"],"gpt_icon":0},{"id":"2492345829","title":"歌礼制药(01672)盘初升逾5% ASC47与司美格鲁肽联合用药减重表现积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2492345829","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492345829?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:39","pubTimestamp":1734658798,"startTime":"0","endTime":"0","summary":"金吾财讯 | 歌礼制药 盘初走高，截至发稿，涨5.69%，报2.6港元，成交额60.08万港元。董事会近日宣布，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖小鼠模型研究中显示出令人鼓舞的疗效。ASC47具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。此外，ASC47显示出了良好的耐受性，当前剂量已递增至90mg，无严重不良事件发生，也未发生因不良事件而导致的停药。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1950016","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1515","BK1191","01672","BK1161"],"gpt_icon":0},{"id":"2492404430","title":"【特约大V】邓声兴：美联储暂缓减息拖累 中港股市偏弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2492404430","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492404430?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:36","pubTimestamp":1734658606,"startTime":"0","endTime":"0","summary":"大市全日成交1428亿元。波音反弹2.6%，为升幅最大道指成份股。美国运通和VISA分别上涨1.8%和1.7%。美联储暂缓减息拖累，中港股市偏弱。加之随着美联储开启降息周期，叠加AH高溢价率下港股性价比凸显，港股流动性趋于改善。ASC47是歌礼自主研发的脂肪靶向，具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。ASC47当前正在澳洲进行肥胖症患者临床试验，IIa期研究顶线数据预计将于2025年第二季度公布。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c79fab1755cd027e7e6d309cd133053b","isJumpTheme":false,"source_url":"1950015","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ESmain","OEF","SSO","UPRO","SPY","SH","01672","US30Y.BOND","BK4585","BK1515","US2Y.BOND","IVV","SPXU","OEX","SDS","BK4581","BK4504","US7Y.BOND","BK1574","US5Y.BOND","US6M.BOND","US12M.BOND",".SPX","US10Y.BOND","BK1161","US3Y.BOND","HK0000934320.USD","BK4534","BK4550","BK4559"],"gpt_icon":0},{"id":"2492643599","title":"金十数据全球财经早餐 | 2024年12月20日","url":"https://stock-news.laohu8.com/highlight/detail?id=2492643599","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492643599?lang=zh_cn&edition=full","pubTime":"2024-12-20 07:00","pubTimestamp":1734649200,"startTime":"0","endTime":"0","summary":"美国经济增长意外加速，黄金2600大关得而复失；“超级央行日”落幕，G7考虑强化俄油限价制裁，美国政府关门倒计时……昨夜今晨，全球都发生了哪些大事？","market":"us","thumbnail":"https://img.jin10.com/news/24/12/lRsvlXRQBXEdPenAX_m8v.jpg/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/news/24/12/lRsvlXRQBXEdPenAX_m8v.jpg/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=156530&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["3NVD.UK","NVDD","02013","BIDU","LU2326559502.SGD","LU2125909593.SGD","NVDY","NVDA","BK1589","HTCD.SI","LU0097036916.USD","BK1109","LI","LU2264538146.SGD","NVDX","80700","NVDU","NVD3.UK","01478","01672","LU1629966141.USD","TSLA","IE0032431581.USD","01055","SNVD.UK","IE0008369823.USD","LU1868836757.USD","LU0234572021.USD","000002","EVS.SI","NVD","LU0588546209.SGD","MU","LU0029875118.USD","NVD2.UK","LU1568876251.USD","LU0509642566.USD","NVDS.UK","TSYW.SI","NVIW.SI","2NVD.UK","LU0588545490.SGD","NVDS","HK0000306685.HKD","LU0880133367.SGD","LU2092937148.SGD"],"gpt_icon":1},{"id":"2492128831","title":"歌礼制药-B(01672)12月19日斥资63.44万港元回购26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492128831","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492128831?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:45","pubTimestamp":1734605117,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2024年12月19日，该公司斥资63.44万港元回购26万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","01477","BK1191","BK1574","01672"],"gpt_icon":0},{"id":"2492111990","title":"歌礼制药-B(01672)下跌11.27%，报2.52元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492111990","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492111990?lang=zh_cn&edition=full","pubTime":"2024-12-19 13:58","pubTimestamp":1734587923,"startTime":"0","endTime":"0","summary":"12月19日，歌礼制药-B(01672)盘中下跌11.27%，截至13:58，报2.52元/股，成交1578.12万元。歌礼制药有限公司是一家创新研发驱动型生物科技公司，主要从事病毒性疾病、非酒精性脂肪性肝炎和肿瘤等三大医疗领域的新药研发、生产和商业化。该公司在浙江绍兴滨海新城拥有约17,000平方米的生产基地，设计年产能为1.3亿片，拥有多款在研药物并已取得药品生产许可证。截至2023年年报，歌礼制药-B营业总收入5659.6万元、净利润-1.45亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/19135846577538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01672","01477","BK1515","BK1191","BK1161","BK1574"],"gpt_icon":0},{"id":"2492919919","title":"港股医药板块短线拉升，来凯医药(02105.HK)涨超6%，歌礼制药(01672.HK)涨超2%，开拓药业(09939.HK)、圣诺医药(02898.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492919919","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492919919?lang=zh_cn&edition=full","pubTime":"2024-12-19 10:57","pubTimestamp":1734577079,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["02898","BK1515","02257","09939","01477","BK1161","02105","159718","BK1191","BK1574","01672"],"gpt_icon":0},{"id":"2492719347","title":"歌礼制药减重药物ASC47联合用药显著优于单药疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2492719347","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492719347?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:43","pubTimestamp":1734572616,"startTime":"0","endTime":"0","summary":"财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202412193272970722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","01477","BK1191","01672","BK1161","BK1574"],"gpt_icon":0},{"id":"1187949470","title":"异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关","url":"https://stock-news.laohu8.com/highlight/detail?id=1187949470","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187949470?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:34","pubTimestamp":1734572080,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672)今日盘中出现大跌行情,截至上午收盘,累计下跌5.28%,引发了市场广泛关注。\n\n根据公司公告,歌礼制药与治疗肥胖症的减重不减肌候选药物ASC47有关。公告显示,ASC47与司美格鲁肽联合用药在临床前模型中虽显示出优于司美格鲁肽单药的减重效果,但整体效果依然疲软,远未达到市场预期。\n\n一些分析人士指出,作为公司主要在研管线之一,ASC47的疗效不达预期可能加大了市场对公司长期前景的疑虑,因此引发了投资者的担忧情绪,从而导致公司股价今日大幅下挫。不过,临床前研究数据并不代表最终疗效,公司尚需进一步开展临床研究,ASC47的前景有待观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01672"],"gpt_icon":0},{"id":"2492160043","title":"歌礼制药-B盘中异动 股价大跌5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492160043","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492160043?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:32","pubTimestamp":1734571945,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘09时32分，歌礼制药-B股票出现波动，股价急速下跌5.28%。截至发稿，该股报2.690港元/股，成交量40.5万股，换手率0.04%，振幅5.28%。资金方面，该股资金流入50.617万港元，流出23.88万港元。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.64%。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093225984cbfb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093225984cbfb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1161","01672","BK1191","BK1574","BK1515"],"gpt_icon":0},{"id":"2492652791","title":"金十数据全球财经早餐 | 2024年12月19日","url":"https://stock-news.laohu8.com/highlight/detail?id=2492652791","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492652791?lang=zh_cn&edition=full","pubTime":"2024-12-19 07:00","pubTimestamp":1734562800,"startTime":"0","endTime":"0","summary":"美联储深夜放鹰，明年降息预期意外砍半！美指暴拉至两年新高，黄金跌超50美元！哈马斯称加沙停火协议谈判取得重大进展……昨夜今晨，全球都发生了哪些大事？","market":"hk","thumbnail":"https://img.jin10.com/news/24/12/lRsvlXRQBXEdPenAX_m8v.jpg/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/news/24/12/lRsvlXRQBXEdPenAX_m8v.jpg/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=156414&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["LU2272731865.HKD","OEX","AVGO","CR","NVD","ESmain","IVV","TSYW.SI","NVDS","LU1934455863.HKD","NVDA","LU0353189680.USD","NVDS.UK","SPY","NVDD","NVIW.SI","NIO.SI","NVDU","09866",".SPX","01088","01672","2NVD.UK","SDS","NVD2.UK","TSLA","3NVD.UK","LU1116320737.USD","NVDX","UPRO","NVD3.UK","NIO","01456","NVDY","SPXU","OEF","SH","EVS.SI","09988","LU1280957306.USD","LU2473716301.USD","SSO","SNVD.UK","LU0912757837.SGD","BABA","BK1505"],"gpt_icon":1},{"id":"2492130139","title":"歌礼制药(01672.HK)首创治疗肥胖症候选药ASC47研究显示出鼓舞疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2492130139","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492130139?lang=zh_cn&edition=full","pubTime":"2024-12-19 01:20","pubTimestamp":1734542400,"startTime":"0","endTime":"0","summary":"歌礼制药－Ｂ(01672.HK) 公布，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖(DIO)小鼠模型研究中显示令人鼓舞的疗效。ASC47是歌礼自主研发的脂肪靶向，具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。ASC47当前正在澳洲进行肥胖症患者临床试验，IIa期研究顶线数据预计将于2025年第二季度公布。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200428112816451_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1405066/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1191","BK1515","BK1574","01672","01477"],"gpt_icon":0},{"id":"2492213182","title":"港股公告掘金 | 首程控股拟约14.566亿港元向首钢控股出售约6.07亿股首钢资源股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2492213182","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492213182?lang=zh_cn&edition=full","pubTime":"2024-12-18 23:06","pubTimestamp":1734534404,"startTime":"0","endTime":"0","summary":"【重大事项】创梦天地(01119)与stc play在技术及游戏领域达成合作歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果王朝酒业(00828)拟与酒中先就成立合资公司订立合资合作协议，以位于东台市生产及销售黄酒及陈皮酒首程控股(00697)拟约14.566亿港元向首钢控股出售约6.07亿股首钢资源股份励晶太","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1538","BK1192","BK1216","00575","00828","BK1591","00639","HSTECH","BK1225","BK1161","01119","BK1500","01672","BK1574","BK1531","BK1104","YANG","HSCEI","BK1516","00697"],"gpt_icon":1},{"id":"2492185407","title":"歌礼制药-B(01672)：治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185407","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492185407?lang=zh_cn&edition=full","pubTime":"2024-12-18 21:32","pubTimestamp":1734528764,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，同类首创治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在饮食诱导肥胖小鼠模型研究中显示出令人鼓舞的疗效。ASC47具有独特的差异化特性，能够靶向脂肪，从而在脂肪组织中产生剂量依赖性的高药物浓度。常规剂量ASC47使肌肉总量增加5.8%，而司美格鲁肽使肌肉总量减少9.3%。低剂量ASC47联合用药1优于司美格鲁肽单药疗法，联合用药使体重下降36.2%，司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1226768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","BK1161","BK1515","01477","BK1191"],"gpt_icon":0},{"id":"2492901978","title":"歌礼制药：恒指收涨 0.83% 生物医药走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2492901978","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492901978?lang=zh_cn&edition=full","pubTime":"2024-12-18 16:33","pubTimestamp":1734510825,"startTime":"0","endTime":"0","summary":"【港股收评：恒指午后再度冲击两万大关未 生物医药板块走强】恒指在录得三连阴后，早间高开反弹，之后震荡低走。午后伴随 A 股冲高，其再度测试两万点大关，未突破后回落，维持水上震荡。截至今日收盘，恒生指数收涨 0.83%，报 19864.55 点。恒生科技指数收涨 1.82%，报 4468.85 点，恒指大市成交额为 1075.41 亿港元。盘面上，科网股表现强势，汽车股、生物医药股回暖造好，航空股、煤炭股午后跌幅扩大。个股方面，歌礼制药收涨 19.33%，国联证券收跌 3.94%，理想汽车收涨 5.45%，小鹏汽车收涨 4.05%，中国神华收跌 1.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218191138ab81a956&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218191138ab81a956&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","02833","BK1574","HHImain","BK1161","01477","BK1515","MCHmain","HSI","BK1191","513600"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.293},{"period":"1month","weight":0.6548},{"period":"3month","weight":1.78},{"period":"6month","weight":2.0889},{"period":"1year","weight":0.6951},{"period":"ytd","weight":0.9041}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0801},{"period":"6month","weight":0.0939},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1568}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品的研发、生产、营销及销售的中国投资控股公司。该公司主要专注于病毒性疾病、非酒精性脂肪性肝炎及肿瘤领域。病毒性疾病产品管线包括利托那韦、盐酸拉维达韦、达诺瑞韦钠等。非酒精性脂肪性肝炎产品管线包括ASC40、ASC41、ASC42等。肿瘤产品管线包括ASC60、ASC61等。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.102992},{"month":2,"riseRate":0.666667,"avgChangeRate":0.004802},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.105976},{"month":4,"riseRate":0.5,"avgChangeRate":-0.033468},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.025765},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.058787},{"month":7,"riseRate":0.5,"avgChangeRate":0.006985},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.090298},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.044648},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.021896},{"month":11,"riseRate":0.857143,"avgChangeRate":0.138187},{"month":12,"riseRate":0.571429,"avgChangeRate":0.110242}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}